Sponsors of an approved antibiotic with a qualified infectious disease product (QIPD) designation could transfer or sell up to 12 months of that exclusivity to different products under draft biomedical reform legislation released by the House Energy and Commerce Committee January 27.
The idea is to encourage new antibiotic development, a public health necessity but not terribly profitable arena, by allowing companies to use the antibiotic